ALEC vs. RGNX, NK, ITOS, CCCC, BDTX, AMRX, DCPH, PTGX, CPRX, and ARVN
Should you be buying Alector stock or one of its competitors? The main competitors of Alector include REGENXBIO (RGNX), NantKwest (NK), iTeos Therapeutics (ITOS), C4 Therapeutics (CCCC), Black Diamond Therapeutics (BDTX), Amneal Pharmaceuticals (AMRX), Deciphera Pharmaceuticals (DCPH), Protagonist Therapeutics (PTGX), Catalyst Pharmaceuticals (CPRX), and Arvinas (ARVN). These companies are all part of the "medical" sector.
Alector (NASDAQ:ALEC) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, community ranking, earnings, valuation and analyst recommendations.
Alector has a net margin of -125.11% compared to REGENXBIO's net margin of -299.96%. REGENXBIO's return on equity of -70.72% beat Alector's return on equity.
85.8% of Alector shares are held by institutional investors. Comparatively, 88.1% of REGENXBIO shares are held by institutional investors. 9.1% of Alector shares are held by company insiders. Comparatively, 13.1% of REGENXBIO shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Alector currently has a consensus target price of $14.00, suggesting a potential upside of 120.13%. REGENXBIO has a consensus target price of $38.58, suggesting a potential upside of 170.95%. Given REGENXBIO's stronger consensus rating and higher possible upside, analysts clearly believe REGENXBIO is more favorable than Alector.
In the previous week, Alector and Alector both had 5 articles in the media. Alector's average media sentiment score of 0.80 beat REGENXBIO's score of 0.38 indicating that Alector is being referred to more favorably in the media.
REGENXBIO received 278 more outperform votes than Alector when rated by MarketBeat users. Likewise, 65.64% of users gave REGENXBIO an outperform vote while only 60.91% of users gave Alector an outperform vote.
Alector has higher revenue and earnings than REGENXBIO. Alector is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.
Alector has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, REGENXBIO has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500.
Summary
REGENXBIO beats Alector on 11 of the 17 factors compared between the two stocks.
Get Alector News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALEC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
Free ALEC Stock Alerts